Real-world lecanemab in Chinese patients: low ARIA, financial-driven discontinuation

This large single-arm Chinese cohort provides pharmacists real-world safety, monitoring, and access data for lecanemab that extend beyond the Clarity Alzheimer's Disease (Clarity AD) trial population.

lecanemabanti-amyloid monoclonal antibodyAlzheimer's diseaseARIAblood-based biomarkersApoEreal-world studyobservational cohortChinaneuropharmacology Neurology / Neuropharmacology

Background Information

Lecanemab shows safety but no cognitive boost in real-world AD study.

Lecanemab's safety and effectiveness in Alzheimer's disease (AD) need assessment in diverse populations. In 1,042 patients, amyloid-related imaging abnormalities occurred in 7.87% and infusion-related reactions in 16.12%. No change in Clinical Dementia Rating Scale-Sum of Boxes was seen at 12 months. The study shows lecanemab has a favorable safety profile but no notable cognitive improvement, highlighting the need for more research with control groups. Lecanemab demonstrates safety but no cognitive improvement in this 12-month study.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y

Citation: Wu H, Chen Q, Fang M, et al. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026;22(8):e71702. doi:10.1002/alz.71702

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →